Imugene Sets Azer-Cel Milestones, Reports 77% Phase 1b Response Rate
IMU: $0.034 -5.56% · MC: $20M
At its AGM, Imugene said azer-cel had a 77% response rate across Phase 1b patients, with early BTK-inhibitor combination data showing an 86% response rate; the company cautioned that the combination results are early. It expects to complete Phase 1b enrolment in the second quarter of 2027, plans an FDA meeting in mid-2027 to discuss the registration pathway, and is targeting a registrational study in the second half of 2027 or 2028, while out-licensing discussions are underway. The AGM also approved all resolutions, and non-executive director Lesley Russell resigned, prompting committee changes.

Comments